PharmacovigilanceOfficial

CMS finalises 2027 outpatient rule, cutting patient costs for 340B drugs and imaging

🇺🇸 CMS · Wed 04 Nov 2026

The Medicare final rule sets 2027 hospital outpatient and ASC payment rates, widens outpatient surgery options and lowers beneficiary out-of-pocket costs for certain services.

The US Centers for Medicare & Medicaid Services (CMS) has issued a final rule for Medicare outpatient services, published on 4 November 2026. It sets payment rates for 2027 for hospital outpatient departments and ambulatory surgical centres (ASCs).

According to CMS, the rule expands the range of surgical procedures that can be performed in outpatient settings. It also lowers out-of-pocket costs for Medicare beneficiaries for imaging services and for drugs acquired under the 340B programme.

The agency also says the rule strengthens oversight of selected services. The material available to VigiEye does not give details of which services are covered, how the 340B payment changes are calculated, or the size of the cost reductions.

The rule is mainly relevant to reimbursement and market access, with the 340B drug payment changes the most significant element for pharmaceutical stakeholders. It has little direct bearing on pharmacovigilance or product safety.

What it means for your team

  • Market-access and pricing teams should review the full final rule text to assess how the 340B drug payment changes affect reimbursement for their products in hospital outpatient settings.
  • Lower beneficiary cost-sharing for 340B drugs may be relevant to patient affordability and utilisation assumptions, though the available summary does not quantify the effect.
  • Regulatory and PV teams are unlikely to face direct obligations from this rule, as it concerns payment and oversight rather than product safety.

Official source: CMS ↗

Article written by VigiEye from the official source (CMS). AI-assisted; check the source before acting.

More Pharmacovigilance All →